Long time investor, retired from tech space
United States
Joined July 2020
- Tweets4.2K
- Following313
- Followers1.1K
- Likes1.7K
Pinned Tweet
$GANX Gain Therapeutics. Good article. Only Parkinson’s drug in history to return smell/taste.
healio.com/news/neurology/20…
reddit.com/r/GANX/s/HWAC1oOL…
joe iniowa retweeted
Today, @HostDigital_ ($HOST) announced a $15 million share buyback program.
Our share price hasn’t changed the power available at Site I or the signed 15-year take-or-pay lease behind it. Our top priority remains financing, developing, and delivering our contracted projects.
joe iniowa retweeted
A megawatt on paper doesn’t do much for anybody. A megawatt that’s energized, leased, financed, built, and collecting rent is what creates value per share. That's our focus at @HostDigital_.
joe iniowa retweeted
Coya today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (#ALS).
We plan to initiate the OLE in response to requests from ALSTARS investigators and study participants. “The strong interest from investigators and participants in continuing treatment beyond the current 48-week study period underscores the importance of providing continued access to COYA 302 for eligible participants in the ALSTARS trial,” said Dr. Fred Grossman, DO, FAPA, our President and Chief Medical Officer.
For more details: businesswire.com/news/home/2…
#EndALS
$GANX Nice to see recognition of stable motor symptoms for Parkinson’s.
Explore the details: bit.ly/4y1zysH
Treatment with a newly named oral therapy for Parkinson's in a small early study led to stable motor symptoms for participants after one year.
#ParkinsonsDisease #PD #ParkinsonsNewsToday #Bionews
$GANX Expecting additional 360 day data this week in addition to the UPDRS scores showing stable or improvement in Parkinson’s which is a world first accomplishment. Premeir International Conference starts today in Seoul Korea.
1/3 $GANX - Following my May review on GANX, herewith a new update with a somewhat evolved template, before the 7th of October presentation. So, actually I'm a bit too early, but I believe there is high likelyhood of a share price rerating. Do your own dd. Bullish on $GANX
happy reading!
note: this is my own research for my own portfolio. It suffers from all kinds of biases and convictions. written content is my own, but supported by ai agents for frequent bayesian scoring and report generation.
joe iniowa retweeted
$GANX just released 12 month data on Parkinsons Disease. Absolutely no progression on phase 1b patients MDS-UPDRS scores in a year, this is a massive win for PD! @ParkinsonDotOrg @ParkinsonsUK @ParkinsonFEP @parkinsons @CureParkinsonsT @MichaelJFoxOrg
joe iniowa retweeted
Lou! Did you see their news today? Crazy market kinda yawned. Seems important $GANX
$GANX First company to stop Parkinson’s progression. Historic data.
$GANX NEWS IS STUNNING
Stock Doesn’t Move…
“In the 12 evaluable participants, MDS-UPDRS motor scores were stable over the 12-month study period with rexaceract, demonstrating no clinically meaningful progression of motor symptoms”
🤯🤯🤯 READ THIS
globenewswire.com/news-relea…
$GANX The 360 day data for Rexaceract will be the first drug that ever has changed the progression of a neurological disease. Literally priceless and a market cap of $80 million.
$GANX Never more...know what you own. It is about to finally get real imo. This is a billion dollar takeover target, with pharma already at the table and that price would be literally giving it away. rexaceract likely may end ends up in the company of insulin, aspirin, penicillin, the smallpox vaccine and morphine.
Much like I said early on both $PRVB and $ABCL just recently, now up almost 3X and going higher. $COYA and Gain complete the trifecta.
$GANX Gain Therapeutics This is the 360 day data that shows the stopping of Parkinson’s progression.
$GANX
Gain Therapeutics to Present GT-02287 (Rexaceract) in people with Parkinson’s disease data
- Gain Therapeutics will Present a Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders scheduled for October 7, 2026
stocktitan.net/news/GANX/gai…
$GANX Gain Therapeutics. We have seen major runs in front of ever data drop like we will see at International Parkinson’s conference in 2 weeks.
$GANX $1.86 The chart looks ready to pop as we head into early‑October “disease‑modifying” Parkinson’s data. They had me at: “The drug stops Parkinson’s progression.”
Right now, every approved Parkinson’s drug only treats symptoms — none slow, halt, or reverse the underlying neurodegeneration. That’s the entire difference.
If you’re involved, the CEO’s comments are worth a listen: journey.ct.events/view/9cbdf…
$GANX Gain Therapeutics and $COYA Coya Therapeutics. Gain will be presenting phase 1b year Parkinson’s data at Major Parkinson’s conference in 3 weeks. They have said their drug stops Parkinson’s Progression.
Two Tiny Biotech Stocks
Big Pharma Is About to Fight Over
youtu.be/y9G56zEUl0U
$GANX Gain Therapeutics presenting 360 day Parkinson’s trial data in early October showing they have stopped Parkinson's progression at a year on drug.
Wow...sounds like they're making some great leaps to help those with Parkinson's. I plan on buying some tomorrow. I love the Fibonacci technicals with price support 1.70-1.95. Thank you @LouBasenese ! $GANX
$GANX Participants provided unsolicited descriptions of perceived benefit after 90 days of dosing. Perceived benefits most commonly described included four instances of improved sense of smell and taste, four instances of improved balance or gait,three instances of improved sleep
$GANX
The actual facts:
• Brain-penetrant drug with demonstrated CNS target engagement
• 81% average CSF GluSph reduction in high-baseline patients
• Biomarker response correlated with clinical benefit
• Durable MDS-UPDRS response through Days 270/360
• Overall cohort remains non-progressive through one year
• Independent DMC recommended continuing unchanged
• FDA-cleared IND with Phase 2 expected Q3
• Early development supported by the Michael J. Fox Foundation
Tiny, open-label Phase 1b that still needs placebo-controlled confirmation? Absolutely—that’s the legitimate bear case.
But “worthless piece of shit” isn’t analysis. Phase 2 will decide whether this signal is real.
$GANX Gain Therapeutics Q2 Report. Parkinson’s worlds first. NO Progression.
The overall patient group continues to benefit from non-progression of their Parkinson’s symptoms through Day 360.
mailchi.mp/7b8c8e5f46e7/gain…
$GANX Gain Therapeutics. Great article on Parkinson’s Disease Modifying approach.
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr | PharmExec
pharmexec.com/view/moving-sy…
Key Takeaways
reddit.com/r/GANX/s/WcMiLewq…
$GANX Gain Therapeutics. Excellent article on the company.
reddit.com/r/GANX/s/LKO1FSDC…
$GANX Gain Therapeutics
Truth, Justice, The American Way, And GT-02287 - TalkMarkets
talkmarkets.com/article/trut…
$GANX Plenty of info out there before the next report out.
r/biotech_stocks] Gain Therapeutics GANX stops Parkinson’s Progression on 16/16 Patients
reddit.com/r/biotech_stocks/…
$GANX @Deancain (900K followers) sees the upside in GT‑02287. The 270‑day readout is almost here, and the 360‑day data hits about three months after that. Open‑label trial, CEO calling his shot like Babe Ruth pointing to deep center — makes you wonder what he’s seeing.
gaintherapeutics.com/newsroo…